Pharma Supply Chain Reshoring

API concentration risk exposed · CHIPS-style legislation for pharma advancing

✦ OPPORTUNITY

COVID-19 exposed dangerous concentration of pharmaceutical API manufacturing in China and India. The US, EU, and Japan are investing heavily in domestic biologics and generic drug manufacturing capacity. CHIPS-style legislation for pharma is advancing. Companies building domestic capacity are capturing long-term government contracts.

Signals

Opp Countries

Risk Countries

Intelligence Evidence — Showing the work

No signals matched yet — check back as new intelligence is collected.

Key Companies — Winners & Losers

✦ OPPORTUNITIES

UBSUBS Group AGEARLY ALLThe Allstate CorporationEARLY IBNICICI Bank LimitedEARLY CCitigroup Inc.EARLY PGRThe Progressive CorporationEARLY

⚠ RISKS

DBDeutsche Bank AGAVOID VVisa Inc.AVOID

Country Opportunities

🇮🇪IrelandNEUTRAL 🇮🇳IndiaWATCH 🇸🇬SingaporeNEUTRAL 🇺🇸United StatesEARLY

Country Risks

🇨🇳ChinaREDUCE

Sector Impact

🏦Financials⚠ RISK

No active themes in global financials. 3 routine OFAC updates this week. EM central bank pivot signals are tracked under the Turkey and EM opportunity themes.